% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • pkpd2105 pkpd2105 Jul 29, 2013 7:40 PM Flag


    Based on Sunesis press release it seems that vosaroxin might be a weak agent...quite unfortunate because AML is so hard to treat and needs new drugs
    The sample size in Valor was increased before to 675 and now further increased to 725 subjects...the bigger the study population the better chance that even smaller difference between treatment arms would become significantly different...however if the difference is small than there is a question if such difference is clinically significant...and more subjects in the trial cost more $$$$ to complete the trial....Good luck seems that hedgies figured it out

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.88-0.04(-4.35%)Aug 29 3:59 PMEDT